This article reviews some recent aspects of pharmacovigilance, of interest to the practitioner: biphosphonates and osteonecrosis of the jaw, antidepressants and suicide, antipsychotics and increased mortality risk and cerebrovascular events, withdrawal syndrome after in utero exposure to antidepressants SSRI, NSAIDs and increased cardiovascular events, cancer and topical immunosuppressants, visual loss and treatment of erectile dysfunction, valvulopathy and dopaminergic agonists. Risk-benefit assessment of drugs is a dynamic process. One must keep in mind that the data on the relationship between drugs and the clinical picture are of variable quality and that the size of the risk is often difficult to assess.